A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

Prostate Adenocarcinoma Clinical Trial

Official title:

PLATPARP: A Phase II Single-Arm Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04288687
• Other study ID #: UPCC 21819
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: October 19, 2020
• Est. completion date: June 2024

Study information

• Verified date: February 2024
• Source: Abramson Cancer Center at Penn Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to evaluate the initial safety and effectiveness of an investigational drug, niraparib, given to patients who have recently received platinum-based chemotherapy for the treatment of prostate cancer. The study enrolls participants with history of advanced prostate cancer that is growing despite standard hormonal therapies, such as androgen-deprivation therapy.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 12
• Est. completion date: June 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma (mixed histology will be acceptable, but pure small cell histology is to be excluded).

2. = 18 years of age.

3. No prior therapy with PARP inhibitor therapy.

4. Patients must have received at least 9 weeks of platinum-based chemotherapy for the treatment of mCRPC as the proximal treatment regimen prior to study screening. Patients must not have evidence of clinical or radiographic disease progression (per Investigator assessment) and should have adequately recovered from chemotherapy-related toxicities (at least 4 weeks following completion of chemotherapy, with treatment-related toxicities = grade 1 per CTCAE version 5).

5. ECOG performance status of = 2.

6. Documented evidence of a pathogenic or likely pathogenic DNA repair aberration in BRCA1/2, ATM, FANCA, PALB2, CHEK2, HDAC2, or BRIP1 through either somatic or germline testing from a CLIA certified laboratory.

7. Radiographic evidence for metastatic disease. Measureable disease (per RECIST) is not required for enrollment. (i.e. bone-only metastatic disease is permitted).

8. Patients with history of treated brain metastases are eligible if off systemic corticosteroids for at least 2 weeks.

9. Clinical evidence for castration-resistance, with total testosterone < 50 ng/dL. Patients who have not undergone bilateral orchiectomy must plan to continue ongoing androgen deprivation therapy for the duration of the trial therapy.

10. Patients must have adequate organ function, as confirmed by laboratory values obtained = 14 calendar days prior to the first day of study therapy: Hematologic: Absolute neutrophil count (ANC) = 1.5 × 109/L, platelet count = 100 × 109/L, and hemoglobin = 9 g/dL (may have been transfused) Hepatic: Total bilirubin level = 1.5 × the upper limit of normal (ULN) range and AST and ALT levels = 2.5 × ULN or AST and ALT levels = 5 x ULN (for subjects with documented metastatic disease to the liver). (Note: In subjects with Gilbert's syndrome, if total bilirubin is >1.5 × ULN, measure direct and indirect bilirubin and if direct bilirubin is =1.5 × ULN, subject may be eligible) Renal: Estimated creatinine clearance = 45 mL/min using Cockcroft Gault formula.

11. Patients must have a projected life expectancy of at least 3 months.

Exclusion Criteria:

1. Prior therapy with a PARP inhibitor.

2. Presence of clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (= New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.

3. Presence of known significant immunodeficiency, as determined by the treating investigator.

4. Presence of clinically significant active infections, as determined by the treating investigator.

5. Known allergy to niraparib or any of its components.

6. Prostate cancer with histologic evidence for pure small cell histology

Related Conditions & MeSH terms

• Adenocarcinoma
• Prostate Adenocarcinoma

Intervention

Drug:
• Niraparib Pill
Niraparib 200 mg by mouth daily (2 x 100 mg pills)

Locations

Country	Name	City	State
United States	Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Abramson Cancer Center at Penn Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	rPFS6	Assessment of the 6-month radiographic progression-free survival (rPFS) rate in patients with platinum-sensitive mCRPC harboring germline or somatic DNA repair defects as determined by Kaplan-Meier analysis.	6 months
Secondary	PSA30	Proportion of patients achieving a =30% decline in PSA following the initiation of niraparib maintenance therapy	3 months
Secondary	PSA50	Proportion of patients achieving a =50% decline in PSA following the initiation of niraparib maintenance therapy	3 months
Secondary	Time to PSA progression	Time until the first PSA increase that is >25% (and an absolute increase of = 2 ng/ml) from the nadir PSA value following the initiation of niraparib maintenance therapy	6 months
Secondary	Frequency and severity of adverse events (AEs)	Frequency and severity of adverse events (AEs), as assessed by CTCAE version 5.0, following the initiation of niraparib maintenance therapy	1 month
Secondary	Overall survival (OS)	Time from start of study therapy to death due to any cause. Patients who are alive will be censored on the most recent date of patient contact	12 months